Abstract
Therapeutic options for the treatment of colorectal cancer (CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hypermutated tumors suggests a permanent role of immune therapy in the clinical management of CRC. Substantial improvement in treatment outcome could be achieved by development of efficient patient-individual CRC vaccination strategies. This mini-review summarizes the current knowledge on the two general classes of targets: tumor-associated antigens (TAAs) and tumorspecific antigens. TAAs like carcinoembryonic antigen and melanoma associated antigen are present in and shared by a subgroup of patients and a variety of clinical studies examined the efficacy of different TAA-derived peptide vaccines. Combinations of several TAAs as the next step and the development of personalized TAA-based peptide vaccines are discussed. Improvements of peptidebased vaccines achievable by adjuvants and immunestimulatory chemotherapeutics are highlighted. Finally, we sum up clinical studies using tumor-specific antigens -in CRC almost exclusively neoantigens -which revealed promising results; particularly no severe adverse events were reported so far. Critical progress for clinical outcomes can be expected by individualizing neoantigen-based peptide vaccines and combining them with immunestimulatory chemotherapeutics and immune checkpoint inhibitors. In light of these data and latest developments, truly personalized neoantigen-based peptide vaccines can be expected to fulfill modern precision medicine's requirements and will manifest as treatment pillar for routine clinical management of CRC.
REVIEW

INTRODUCTION
Therapy of colorectal carcinoma (CRC) has been im proved over the years with advanced surgical and che motherapeutic procedures but challenges in sight of efficiency and adverse effects must still be accomplished. Especially late stage CRC patients still have a relatively poor prognosis. Only recently, immunotherapy has rea ched general clinical acceptance with the breakthrough results of immune checkpoint inhibition for selected cancer types or subgroups also for CRC.
One approach further improving this type of CRC therapy is the vaccination with peptides alone, peptide expressing viruses, peptideloaded antigen presenting cells or application of peptidespecific T cells. Historically, the development of such cancer vaccines started with peptides derived from tumorassociated antigens (TAAs).
TAAs
TAAs are proteins that are significantly overexpressed in cancer compared to normal cells and are therefore also abundantly presented on the cancer cell's surface. Peptides of these TAAs bound to human leukocyte anti gen (HLA) can be recognized by T cells initiating an anti cancer immune response ( Figure 1 ). Therefore, these TAAs have been used as target structures for the devel opment of cancer vaccines (see Table 1 for an overview of CRC focused clinical studies).
Carcinoembryonic antigen
One of the first TAAs ever identified was the carcino embryonic antigen (CEA) which is also overexpressed in CRC [1] . In initial in vitro experiments, it could be proven that CEAderived peptideloaded dendritic cells (DCs) are able to induce CEAspecific cytotoxic T lymphocyte (CTL) activity [2] . However, a CEAderived peptide with low avidity led to an inefficient immune response lacking activated CTLs [3] . The explanation for such inefficient T cell activation lies in the fact that TAAs like CEA are not really cancer specific but are also expressed by normal epithelial cells. Therefore, the organism must, for the most part, be tolerant to such TAAs in order to prevent autoimmunity.
Consequently, different approaches for modifying CEA vaccines were developed to overcome or weaken this immune tolerance. Using an altered peptide ligand of CEA with higher HLA binding affinity could efficiently activate specific CTLs in vitro [4] . Another way to enhance specific T cell activation was the development of DNA vaccines encoding the CEAderived peptide(s) together with sequences for stimulating cytokines, adjuvants or supportive T helper cell epitopes. In murine models, this kind of vaccine showed higher T cell activation in comparison to peptideonly vaccines [5, 6] . However, in clinical trials, the efficacy of CEA peptide vaccines was overall not satisfying, clinical response rate did not exceed 17 % [710] .
Melanoma associated antigen
The melanoma associated antigen (MAGE), first dis covered in melanomas, belongs to the group of cancer/ testis antigens. This subgroup of TAAs is expressed only in testis and cancer cells. MAGE has subsequently been found to be expressed in the majority of adeno carcinomas. The rate of CRCs identified as being MAGE positive strongly varied between different studies and MAGE variants: 14 % for MAGEA [11] , 51 % for MAGEA16 [12] and 28 % for MAGEA3 [13] . A clinical benefit by a MAGEdirected vaccination therapy could be shown in a case study by Takahashi et al [14] . They reported that a synthesized helper/killer hybrid epitope long peptide of MAGEA4 is able to induce an orchestrated CD4 + and CD8 + immune re sponse leading to a slightly decreased tumor growth and resulting in stable disease. In a vaccination study investigating different TAAs, an increase in specific CTLs could be detected but clinical response was not ob served [15] .
Other TAAs
Progress in CRC vaccine development was made also with a variety of other TAAs. A peptide vaccination consisting of two different 9mers derived from MUC1 combined with CpG oligonucleotides and granulocyte macrophage colonystimulating factor (GMCSF) as adjuvants reduced tumor burden in a MUC1.Tg mouse model. In the prophylactic setting, even a complete protection against a syngeneic colon cancer cell line was achieved and attributed to the MUC 1specific activation of the immune system [16] . However, these promising results could not be proven in clinical trials. Although an increase in anti MUC1 IgGs could be detected, neither cellular nor clinical response was observed [1719] . CRC patients treated with survivinderived peptide pulsed DCs showed an increased number of specific CTLs [20, 21] . In a minority of patients, also a drop in level of tumor markers and even in total tumor volume was wit nessed [21] . Furthermore, success was achieved in CRCfocused studies on vaccination with peptides obtained from Wilms tumor 1 protein [22] , transmembrane 4 superfamily member 5 protein [23] , mitotic centromere associated kinesin [24] and epidermal growth factor receptor [25] . Of note and in contrast to other tumor entities, NY ESO1 is not overexpressed in CRC [11, 26, 27] and has therefore not been exploited as a target for immuno therapy.
COMBINATION OF TAAs
Single peptide vaccines often showed a significant immune response which was, however, not accompanied by a significant reduction of tumor burden. Thus, sub sequent vaccination studies included more than one TAA derived peptide to ameliorate clinical response. After the identification of the ring finger protein 43 (RNF43) as a CTLinducing peptide [28] , it was often investigated in combination with other peptides. At first Okuno et al [29] combined chemotherapy with a RNF43
and a 34kDa translocase of the outer mitochondrial membrane (TOMM34) peptide in a phase Ⅰ clinical trial which resulted in 83 % stable disease and a mean survival time of 24 mo, but no reduction in tumor burden was observed. The efficiency of inducing specific CTLs by RNF43 and TOMM34 was also proven by additional the number of vaccine peptidespecific CTL responses and overall survival [32] . Similar results were observed in a vaccination study with peptides from RNF43, TOMM34, VEGFR1 and VEGFR2 as well as insulinlike growth factorⅡ mRNA binding protein 3 [33] .
PERSONALIZED PEPTIDE VACCINES
To further enhance the efficiency of cancer vaccines, the next wave of trials focused on personalized pep studies [30, 31] . To further improve clinical response, Okuno et al [32] tested a seven peptide vaccine containing peptides from RNF43, TOMM34, forkhead box M1, maternal embryonic leucine zipperkinase, holliday junction recognizing protein and vascular endothelial growth factor receptor 1 and 2 (VEGFR1 and VEGFR2). In 9 out of 30 vaccinated patients, a CTL response to all 7 peptides could be de tected including two of the three partial responders of the study. Moreover, there was a correlation between tide vaccines. This personalization was achieved by measuring existing peptidespecific CTL precursors in the patients' blood, as well as screening for peptidespecific IgGs, followed by vaccination with CTLreactive peptides. In a phase Ⅰ clinical trial, Sato et al [34] treated 10 CRC patients with 24 matching peptides derived from cytochrom B, intestinal cell kinase, squamous cell carci noma antigen recognized by T cells (SART)13 and ADP ribosyltransferase 4. Peptide specific CTLs increased in 50 % of patients, peptide specific IgGs in 60 %. In half of the patients an elevated functional CTL activity was observed in cytotoxicity assays. In spite of this enhanced immune response, only two patients could clinically bene fit from vaccination and had a partial response (reduction of metastasis' volume) and a stable disease, respectively. In a subsequent study, the effect of a personalized peptide vaccine in combination with a 5fluorouracil deri vative was investigated [35] . After six vaccinations, six out of seven patients responded to at least one peptide with increased CTL and IgG levels. But only one patient showed stable disease. He responded to peptides derived from SART3, Tyrosineprotein kinase Lck and WolfHirsch horn syndrome protein.
The combination of personalized peptide vaccination and chemotherapy resulting in clinical benefit was also proven in a further study. Hattori et al. vaccinated 14 metastatic CRC patients with up to four personal HLA matched peptides. This was combined with a 5fluoruracil based standard chemotherapy [36] . Although neither partial nor complete responses were obtained, three patients showed minor response, defined as a reduction in tumor size. Furthermore, three additional patients had stable disease. The strongest immune responses were induced by peptides derived from SART2/3, multidrug resistanceassociated protein 3, Her2/neu, cytochrome B, ubiquitinconjugating enzyme E2 and CEA.
Besides, it could be proven that the number of pep tides with increased CTL responses after vaccination was also significantly predictive of favorable overall survival [37] similar to the correlation found in studies with combinations of TAA vaccines [32] .
NEOANTIGENS -TRULY TUMOR-SPECIFIC ANTIGENS
The stepwise acquisition and accumulation of mutations has been generally recognized as major mechanism for cancer initiation and progression. It not only leads to enhanced or reduced expression of genes but also to the expression of sequencemodified proteins the socalled neoantigens (see Figure 1) . Hence, the probability of creating neoantigens is rising simply with the number of mutations present in a given cancer cell [38] . But the muta tional burden and therefore the potential of expressing neoantigens varies clearly between different cancer entities. The highest somatic mutation frequency of around 10 mutations per megabase is found in cancers of the skin, lung and colorectum resulting in the expression of approximately 150 nonsynonymous mutations within expressed genes [39] . A hypermutational burden is caused by a deficiency in the mismatch repair system. This leads to replication errors especially in regions with repetitive nucleotides which are found in coding microsatellites. A mismatch repair deficient tumor shows microsatellite instability (MSI) with a huge variety of mutations. A similar or even still higher mutational burden can be caused by a muta tion in the catalytic subunit of DNA polymerase epsilon (POLE) leading to hypermutation independent of MSI.
Because high neoantigen load of CRC has repeatedly been correlated with improved patient survival [40, 41] , neoantigens have only recently been accepted as ideal targets for successful immunotherapy. In addition, as neoantigens are truly tumorspecific antigens (TSA) only presented by cancer cells but not by normal cells, the immune system can easily distinguish between malignant and healthy tissue minimizing the risk of vac cinationinduced severe adverse events (SAEs).
TGFβRII and other frameshift mutations
Studies focused on single nucleotide insertions or dele tions in coding microsatellites and identified several proteins frequently affected by frameshift mutations in MSI high CRCs. Early a short form of the transforming growth factor beta receptor 2 (TGFβRⅡ) was identified as such a frameshifted and therefore truncated protein with a role in tumor progression. It could be proven that a 23mer peptide derived from frameshift mutated TGFβRⅡ is able to induce T cell proliferation predominantly in CD4 + T (helper) cells [42] . This promising result was confirmed by results from a frameshift mutated TGFβRⅡderived 9mer peptide [43] . But in contrast to the former study, the induced T cells were predominantly CD8 + and, more important, these activated T cells were able to lyse TGFβRⅡmutated CRC cells in a HLArestricted fashion. TGFβRⅡmutationreactive T cells were also able to decrease tumor load in a mouse model and even signifi cantly prolong survival [44] underlining the potential of frameshifted TGFβRⅡ as immunotherapeutic target. In further studies, it was proven that peptides derived from frameshifted caspase 5, mutS homologue 3 and Olinked Nacetylglucosamine transferase gene are able to induce CTLs with cytotoxic activity against CRC cells [4547] . In another approach, an antibody response directed against frameshifted homeobox protein CDX2 was detected in serum of a CRC patient [48] . There are several further candidate genes frequently presenting with frameshift mutations in coding micro satellites: PTHL3, HT001, AC1, ACVR2, SLC23A1, BAX, TCF4 and MSH3 [49] . In addition peptides derived from frameshiftmutated MARCKS1, MARCKS2, TAF1B-1, PCNXL22, TCF7L22, Baxα+1 [50] as well as CREBBP, AIM2, EP300 and TTK [51] have been suggested to be taken into consideration for developing cancer vaccines for MSI high CRCs as auspicious experimental and bio informatic data proved their importance. In a first clinical trial, 22 CRC patients received vac cines containing peptides of frameshifted AIM2, HT001 and TAF1B [52] . No vaccinerelated SAEs were observed and the induced immune response was significant: all patients responded to at least one of the peptides.
KRAS: an example of point mutated genes
In the process of cancer development mutations resulting in neoantigens can emerge in every coding region of the DNA. Neoantigens caused by KRAS are one example for point mutations in CRC. KRAS plays a major role in intracellular signaling cascades and is found mutated in more than 40 % of CRCs [53, 54] . Most frequent mutations are located at codon 12 (G12D or G12V mutation) or 13 (G13D mutation) of the KRAS gene and result in single amino acid substitutions in the expressed protein [55, 56] . Early approaches could prove that peptides derived from mutated KRAS can stimulate CTLs in vitro [57, 58] as well as in pancreatic [59, 60] and colorectal cancer [61] . A subsequent study also investigated the cytotoxic activity of mutated KRAS peptideinduced CTLs [62] . Only 2 of 10 CRC patients showed induction of peptide specific CD8
+ but in addition, these cytotoxic T cells were able to lyse HLAA2positive target cells incubated with the 10mer mutant peptide. Similar results were obtained in a xenograft study, where peptidespecific T cells were able to delay the growth of KRAS mutant pancreatic tumors [63] . In vaccination trials with peptides derived from mutated KRAS, clinical benefits for patients could be achieved. Although only two of seven CRC patients re sponded positive to a mutated KRAS peptide vaccination, four remained with no evidence of disease [64] . In a case report, one CRC patient was treated with activated T cells recognizing G12D KRAS [65] . After a single infusion, all seven lung metastases regressed for 9 mo until 1 metastatic lesion progressed.
To further enhance the immunological response in CRC patients, Rahma et al. combined the peptide vac cination of mutated KRAS with IL2 or GMCSF [66] . The strongest immune response could be detected in the group with GMCSF as adjuvant; all CRC patients had an increase in interferon producing, specificallyactivated T cells. Despite the high immune response rate, no patient showed clinical response and disease progressed in all cases. An increase in regulatory T cells, detectable in all CRC patients of this group, is a likely explanation for this negative result.
Other neoantigens
Besides point and frameshift mutations there are fur ther possibilities in creating neoantigens. Mutations at somatic splice sites as well as deregulated splicing factors can lead to alternative splice variants. A large scale systematic investigation revealed that alternative splice variants in CRC are mainly caused by exon skip ping, alternative promoter or terminator and intron re tention [67] . A comparison between CRC and normal cells demonstrated that there are alternative splice variants exclusively expressed by cancer cells [68, 69] . That these altered peptides can be presented by HLA was already proven in a study focusing on melanoma [70] . Therefore, further investigation in this field of alternative splice variants could lead to an extended range of target struc tures for cancer vaccines.
Ditzel et al [71] found a completely different mechanism of neoantigen generation. They proved that the apoptotic markers cytokeratin 8 and 18 are only proteolytically truncated in CRC tissue but not in normal colon epithelia. The cancerassociated forms of cytokeratin 8 and 18 are early apoptosis markers and recognized by a human antibody specific for a heterotypic conformational epitope. However, this and similar epitopes can hardly serve as target structures for T cellspecific immunotherapies.
CHALLENGES FOR DEVELOPING A CRC VACCINE
Genetic configuration and target selection
One important property for the development of a CRC vaccine is the genetic subtype of the patient. Around 15 % of CRCs are MSI high and provide therefore a variety of mutations leading to neoantigens which are, as described above, often derived from frameshift mutations. An other form of hypermutated CRC is caused by POLE mutations but only 3 % of CRC patients fit into this category. MSI high or POLE mutations are responsible for a high mutational burden which is regularly correlated with increased lymphocyte infiltration into the tumors mirroring higher prevaccination antitumoral activity of the patients' immune system. Especially the intratumoral presence of CD8 + CD45RO + T cells correlates with improved survival [72] . A CRC vaccine could further en hance or reactivate this anticancer activity and result in tumor reduction.
But also CRCs without MSI or POLE mutations show multiple genetic alterations. These immunogenic mutations, TAAs or neoantigens, need to be identified for vaccine development. Modern nextgeneration se quencing approaches open up the possibility of easy and fast sequencing but challenges in form of tumor heterogeneity are still to be accomplished. The whole mutational profile of a tumor is difficult to be depicted and for individualized vaccine development, it has to be considered that tumor sequencing can reveal only mutations of a subset of cells and at the time point of operation. The mutational profile of residual metastatic cells might differ [73, 74] . One promising approach is to focus on driver muta tions that are responsible for maintenance of the trans formed status and/or the progression of the individual tumor. Aiming at driver mutations is of advantage in comparison to passenger mutations, as the tumor cell's sur vival is dependent on these dysregulated gene products and therefore, immune escape by switching off or reverting such mutations is less likely to occur.
The concept of personalized peptide vaccination fol lows another approach. CRC patients are screened for the presence of CTLs and IgGs against known TAAs and neoantigens in addition to the determination of their HLA profile. Having the knowledge of the patients' HLA layout as well as the natural immunogenicity of the tumor, the vaccine can be adapted by choosing matching peptides for vaccination. This lowers the risk of SAEs by only en hancing the existing antitumoral immune response.
VACCINE DESIGN
When a promising target is found, the design of the vaccine starts. As mentioned before, suiting (better ideal) peptides as well as adjuvants and administration schedules need to be selected. Due to space restrictions, we focus here on peptidebased vaccination strategies and omit recombinant protein and tumor lysatebased ones.
Single peptides, peptide-loaded antigen-presenting cells or ex vivo expanded T cells?
Peptides used for vaccination can vary in length. When they directly bind into the peptidebinding groove of the HLA molecules, 810mers (HLAA/B/C) or 1318mers (HLADP/DQ/DR) are typically used. But the binding affinities of peptides to different HLA isoforms deviate. In addition, as the patient is restricted to its individual set of HLA alleles, the efficiency of a peptide vaccine is dependent on the selection of peptides and their best matching HLA. Furthermore, most of the current studies have only investigated peptides restricted to the most common HLA alleles HLAA2 or HLAA24, thereby limiting the number of patients benefitting from this therapy.
To circumvent HLA restriction, longer peptides (1530mer), so called synthetic long peptides, can be used as these peptides are internalized, processed and presented by antigen presenting cells. The risk of diges tion by proteases is also decreased as long peptides form a tertiary structure and have therefore a longer half life [75, 76] . Alternatively, using (autologous) cellular vaccine stra tegies, completely evades the problem of HLArestriction and peptide degradation. They can be composed of antigen presenting cells (DCs, B cells or artificial antigen presenting cells [77] ) which present the selected peptide(s) to both CD4 + helper as well as CD8 + effector T cells or the direct approach of applying T cells carrying tumorantigen specific T cell receptor(s). For the latter approach, patient specific T cells need to be isolated, expanded and stimulated in vitro. After this complex ex vivo procedure, a defined amount of functional T cells can be given back to the patient. By including also T helper cells or peptides activating T helper cells, a humoral immune response can be induced, too [14] .
Adjuvants
To further enhance the strength of a vaccine, for mulations typically include also adjuvants. Incomplete
Freund's adjuvant, alum, gold or nanoparticles as well as heat shock proteins and GMCSF are such adjuvants which improve antigen stability, delivery, processing and presentation to T cells [78, 79] . This is achieved by forming a depot at the injection site resulting in slow and prolonged peptide release and/or by induction of proliferation and migration of antigen presenting cells. GMCSF, as well as TNF receptor ligands and TLR agonists like CpG oligo nucleotides, additionally aim at enhancing costimulatory signals for T cell activation. Furthermore, cytokines like interferons or interleukins lead to enhanced immune response in different clinical trials [80, 81] .
ADVERSE EVENTS
Cancer vaccines are characterized by a high safety and low toxicity profile. Different studies evaluated SAEs grade Ⅲ/Ⅳ after cancer vaccine therapy in around 5500 cancer patients and observed a frequency of < 3% [82, 83] . But especially by using vaccination approaches with TAAs, the possibility of damaging healthy tissue should not be neglected. As mentioned above, TAAs are not re stricted to the tumor tissue but only expressed at higher levels compared to (some) normal cells.
In a study with engineered antiCEA T cells, the CEA levels decreased and even tumor regression was seen in one patient; but all treated patients experienced severe transient inflammatory colitis [84] . The treatment with auto logous antiMAGEA3/A9/A12 engineered T cells led in another clinical trial to severe neurological toxicity in 3 out of 9 cancer patients [85] . Recognition of different MAGEA proteins in normal human brain by engineered T cells caused even treatment related mortality in 2 patients. Similarly, the use of engineered T cells showing offtarget effects by recognizing untargeted proteins is associated with an increased risk of SAEs. Linette et al. used an affinityenhanced T cell receptor against MAGEA3 and the first two treated patients developed a cardiogenic shock and died within a few days [86] . Recognition of the striated musclespecific protein titin by these T cells led to severe cardiogenic damage.
As neoantigens are not presented by healthy cells, the risk of SAEs is decreased by using neoantigen targeting vaccines. To date, vaccine studies focusing on neoantigens in CRC patients observed no SAEs; only mild side effects that resolved spontaneously have been described (e.g., injections site reactions, fever) [52, 62, 64, 66] .
CANCER VACCINES: THE SOLUTION TO IMMUNE EVASION?
The tumor microenvironment is characterized by im munosuppressive signals leading to immune evasion of the tumor. An accumulation of regulatory T cells is re sponsible for the downregulation of other infiltrating and tumor attacking T cells in an antigendependent manner or by secretion of IL10 or TGFβ [87] . Furthermore, these signal molecules are able to suppress the maturation of DCs resulting in reduced antigen presentation [88] . Tumor associated macrophages as well as myeloid suppressor cells are also present in the tumor microenvironment and act as immune suppressors [87, 89] . But in addition to creating an inhospitable environ ment for tumor attacking immune cells, tumor cells can also hide from immune cells by modifying their surface to escape recognition. More than 50 % of MSI high CRC patients' tumor harbor mutations that lower the func tionality of HLA presentation of antigens [90] : mutations regarding regulation of HLA expression (e.g., NLRC5 mutation [90] ), peptide transport (e.g., TAP1/2 and tapa sin [9092] ) as well as HLA itself (e.g., heavy chain [90] and B2M mutation [9193] ). To overcome this dissembling mechanism, the use of specific chemotherapeutics can be helpful, leading to an effective antitumor immune response by apoptosis (discussed below).
Furthermore, cancer cells take advantage of the control mechanism of nonsense mediated RNAdecay (NMRD). This system is responsible for degrading mRNA with premature stop codons and it has been suggested that this must inhibit the presentation of neoantigens [94] . However, it could be shown that only a part of the so far identified neoantigens are sensitive to NMRD [51] . Last but not least, cancer cells can not only influence cells of the microenvironment to express immune checkpoint molecules but they frequently express such molecules themselves to downregulate T cell activity. Immune checkpoint inhibitors are a precious device in overcoming this tumorinduced immune suppression.
IMMUNE CHECK POINT INHIBITORS
The field of studies exploring immune checkpoint inhi bitors is growing. Targeted immune checkpoints like CTLA4, PD1, PDL1 and LAG3 are highly expressed in MSI high tumors, thereby creating an immune suppressive microenvironment [95] . Besides, T cells infiltrating in MSI high tumors frequently express PDL1 making a PD1 blocking antibody (e.g., Pembrolizumab) a helpful instrument [96] : In clinical trials, almost 80 % of MSI high CRC patients benefitted from PD1 blockade whereas microsatellite stable (MSS) CRC patients rarely did [96, 97] . This can be explained by the difference in mutational burden of MSI high and MSS patients, as a correlation of mutational burden/number of neoantigens and clinical response could be proven already [98, 99] . Moreover, this clinical observation suggests that a substantial part of the correlation between infiltrating lymphocytes and overall survival is only in MSS patients significant [100, 101] . Therefore, a combined immunotherapy with blocking immune checkpoints on the one hand and stimulating the immune system with a peptide vaccine on the other hand could help MSS as well as MSI high CRC pa tients. A first animal study demonstrated increased cytolysis rate, tumor suppression and survival with a DNA vaccine consisting of PD1 fused with survivin and MUC1 peptides [102] . Clinical trials investigating the effect of immune checkpoint inhibitors with other forms of immunotherapy in CRC patients are still ongoing (Table 2) .
CANCER VACCINES AND IMMUNOGENIC
CELL DEATH
The dogma that chemotherapy is immunosuppressive has been disproved. Contrarily, it could be shown that selected chemotherapeutics are able to induce a special kind of cell death which improves tumor im mune recognition. This so called immunogenic cell death is characterized by damageassociated molecular patterns on the surface of the tumor cell (calreticulin and heat shock proteins) which are "eat me" signals for immune cells and act as costimulators [103] . Inducers of immunogenic cell death are anthracyclines like doxorubicin [104] , DNA alkylating cyclophosphamide [105] as well as the common platinum derivative for CRC treatment, oxaliplatin [106] . The studies combining TAAs with different chemotherapeutic agents also observed no immune suppressive effects but induction of specific immune responses [29, 35, 36] . Therefore, the combination of immunogenic cell death inducing chemotherapeutics and cancerspecific vaccination is an auspicious approach for future treatment of CRC patients (Figure 2) .
Immunogenic cell death can also be induced by on colytic viruses which preferentially infect cancer cells. In vitro studies revealed that viral treatment can lead to killing of CRC cells, especially tumor initiating cells or cancer stem cells [107, 108] . First clinical studies with a combination of oncolytic viruses and immune checkpoint inhibitors in melanoma patients showed response rates up to 62 % [109111] . These promising combinations are currently investigated in clinical trials also including CRC patients (Table 2) .
CONCLUSION
Cancer vaccines are a promising instrument for treatment of cancers. The development started with peptides de rived from TAAs. These targets can be detected easily and are shared by many patients. Therefore, a variety of studies investigated the effect of TAAderived peptide vaccines with mediocre results. Low immunogenicity, HLA restriction as well as increased risk of SAEs limit the efficiency and clinical usefulness of this vaccine type.
These problems can likely be solved with novel vaccination approaches focusing on TSAs, mainly neo antigens. They clearly differ from proteins of healthy cells and thus neither selftolerance nor SAEs are likely to limit clinical application of TSAbased vaccines (see Figure  1) . First in vitro and in vivo studies revealed promising results. It can be envisioned that these advantages will on the longer run compensate for the time and money intense identification of patientindividual neoantigens and peptide composition. Pure peptide vaccines, peptide loaded antigen presenting cells or adoptively transferred T cells will be exploited. To further enhance the effect of neoantigen vaccines, adjuvants will be included. These improve peptide stabi lity and also act as immune stimulators. Besides, the combination of these new generation individual cancer vaccines with immune checkpoint inhibitors and/or im munogenic cell deathinducing chemotherapeutic agents is an utterly promising concept that will be extensively investigated in the near future. Such multifactorial approaches even have the potential to solve the dif ficulties in targeting MSS CRC. However, concepts to select the bestsuited combinations of vaccines, adju vants and chemotherapeutic on a patientindividual basis still have to be developed and possibly even more ambitious adapted to the clinical routine.
